{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:42:56Z","timestamp":1790660576040,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ebiom.2023.104586","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T17:50:30Z","timestamp":1682358630000},"page":"104586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial"],"prefix":"10.1016","volume":"91","author":[{"given":"Yu-Zhou","family":"Gui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Rong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Lei","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Yu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Yin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang-Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi-Jie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Cai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifa","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2492-3219","authenticated-orcid":false,"given":"Jing-Ying","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang-Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2023.104586_bib2","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s41591-022-01892-2","article-title":"Evolutionary insight into the emergence of SARS-CoV-2 variants of concern","volume":"28","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2023.104586_bib3","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41586-022-04690-5","article-title":"Defining the risk of SARS-CoV-2 variants on immune protection","volume":"605","author":"DeGrace","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2023.104586_bib4","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41591-022-01704-7","article-title":"Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination","volume":"28","author":"Cheng","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2023.104586_bib5","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1038\/s41467-022-32321-0","article-title":"Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens","volume":"13","author":"Klemis","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2023.104586_bib6","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1038\/s41467-022-32527-2","article-title":"BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19\/BNT162b2 vaccination against COVID-19","volume":"13","author":"Behrens","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2023.104586_bib7","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1038\/s41467-022-30340-5","article-title":"Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant","volume":"13","author":"Zuo","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2023.104586_bib8","series-title":"Interim recommendations for heterologous COVID-19 vaccine schedules: interim guidance","author":"World Health Organization","year":"2021"},{"key":"10.1016\/j.ebiom.2023.104586_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-069989","article-title":"Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis","volume":"377","author":"Au","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.ebiom.2023.104586_bib10","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2023.104586_bib11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2023.104586_bib12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1473-3099(21)00677-0","article-title":"Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b\/3 trial","volume":"22","author":"Kremsner","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2023.104586_bib13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-021-00634-z","article-title":"A\u00a0core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ebiom.2023.104586_bib14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41422-021-00596-5","article-title":"Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine","volume":"32","author":"Cao","year":"2022","journal-title":"Cell Res"},{"key":"10.1016\/j.ebiom.2023.104586_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2023.104586_bib16","first-page":"39","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Ramanathan","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2023.104586_bib17","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2023.104586_bib18","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2023.104586_bib19","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/s41591-021-01330-9","article-title":"Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study","volume":"27","author":"Li","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2023.104586_bib20","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 \u2014 preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2023.104586_bib21","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A\u00a0bivalent Omicron-containing booster vaccine against Covid-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2023.104586_bib22","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1016\/S2666-5247(21)00305-0","article-title":"Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study","volume":"3","author":"Barin","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ebiom.2023.104586_bib23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJMc2032195","article-title":"Durability of responses after SARS-CoV-2 mRNA-1273 vaccination","volume":"384","author":"Widge","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2023.104586_bib24","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2023.104586_bib25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.13091","article-title":"Correlates of protection against SARS-CoV-2 infection and COVID-19 disease","volume":"310","author":"Goldblatt","year":"2022","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ebiom.2023.104586_bib26","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.cmi.2023.01.008","article-title":"Bivalent BNT162b2mRNA original\/Omicron BA.4-5 booster vaccination: adverse reactions and inability to work compared to the monovalent COVID-19 booster","volume":"29","author":"Wagenh\u00e4user","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ebiom.2023.104586_bib27","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-2600(22)00087-X","article-title":"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial","volume":"10","author":"Li","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ebiom.2023.104586_bib28","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2023.104586_bib29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","article-title":"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study","volume":"399","author":"Costa Clemens","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2023.104586_bib30","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S2213-2600(21)00357-X","article-title":"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study","volume":"9","author":"Hillus","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ebiom.2023.104586_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003953","article-title":"Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia\/ZF2001): a randomized, observer-blinded, placebo-controlled trial","volume":"19","author":"Jin","year":"2022","journal-title":"PLoS Med"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396423001512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396423001512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:21:39Z","timestamp":1762456899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396423001512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":30,"alternative-id":["S2352396423001512"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104586","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104586","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104586"}}